Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future
Date
2018
Authors
Pokorny, Adrian M J
Chin, Venessa
Nagrial, Adnan M
Yip, Desmond
Chantrill, Lorraine
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care
Description
Keywords
Citation
Collections
Source
Internal Medicine Journal
Type
Journal article
Book Title
Entity type
Access Statement
License Rights
Restricted until
2037-12-31
Downloads
File
Description